Management

Management

PAUL E. FREIMAN
President and Chief Executive Officer

Paul E. Freiman joined NTI as a director and was subsequently appointed President and Chief Executive Officer. He is the former Chairman and Chief Executive Officer of Syntex Corporation, where he had a long and successful career and was instrumental in the sale of Syntex’s lead product, Naprosyn, and was responsible for moving the product to over-the-counter status, marketed by Proctor & Gamble as Aleve. Mr. Freiman currently serves as Chairman of the Board of Penwest Pharmaceuticals Co. He serves on the boards of Calypte Biomedical Corporation, NeoPharm Inc., NovaBay Pharmaceuticals, Otsuka America Pharmaceticals, Inc. and SciGen Ltd. He has also been chairman of the Pharmaceutical Manufacturers Association of Amercia (PhRMA) and has also chaired a number of key PhRMA committees. Mr. Freiman is also an advisor to Burrill & Company, a San Francisco merchant bank. Mr. Freiman holds a B.S. degree from Fordham University and an honorary doctorate from the Arnold & Marie Schwartz College of Pharmacy.


MATTHEW M. LOAR
Vice President and Chief Financial Officer

Matthew Loar joined NTI in April 2008. Mr. Loar is a Certified Public Accountant with over 20 years of experience in finance and accounting. He has a strong track record working with growing pharmaceutical and biotechnology companies, and has played a key role in several major corporate collaborations, successfully completing public and private equity financings and implementing the provisions of Sarbanes-Oxley Act at a public biotechnology company. Mr. Loar joined the company from Osteologix, where he served as Chief Financial Officer since 2006. Previously he was Chief Financial Officer at Genelabs Technologies. He graduated from the University of California, Berkeley and is a member of the American Institute of CPAs.


WARREN W. WASIEWSKI, M.D.,
Vice President, Chief Medical Officer

Dr. Warren Wasiewski joined NTI in February 2007. He is a Board Certified Pediatric Neurologist with an extensive clinical career. He joined NTI from AstraZeneca LP, where he was the Sr. Medical Director of Clinical Research CNS/Emerging Products. His career includes 19 years in Pediatric Neurology. Prior to joining AstraZeneca, he was Chairman of Pediatrics at Lancaster General Hospital from 1998 to 2001 and from 1991 to 2001 he was a Consultant Neurologist at Pediatric Neurology Associates in Lancaster, Pennsylvania a practice he founded in 1991. Prior to founding Pediatric Neurology Associates he was an assistant professor of Pediatrics at Penn State Medical School in Hershey PA. Among his professional affiliations, Wasiewski is a Fellow of the American Academy of Neurology, Fellow of the American Academy of Pediatrics, a member of Alpha Omega Alpha the national Medical Honor Society and a member of the American Heart Association. He is widely published in areas of disease of the central nervous system including migraine and stroke.

Dr. Wasiewski holds a Bachelor of Arts in Biology Cum Laude from Rutgers College, a Masters of Science in Biochemistry from State University of New York Downstate Medical Center, and a Doctorate of Medicine from State University of New York, at Buffalo.


DAVID E. LEVY, M.D.
Vice President, Clinical Development

David E. Levy, M.D., was appointed vice president of clinical development of Neurobiological Technologies, Inc. (NTI) in August 2004. Before joining NTI, he was international project team leader at Eisai Medical Research, Inc. where he directed clinical programs for Alzheimer’s disease and acute ischemic stroke. Previously, he served as an advisor to Empire Pharmaceuticals and as senior director of medical research at DOV Pharmaceutical. From 1991 to 2001, Dr. Levy was with Knoll Pharmaceuticals last serving as, senior director of cardiovascular/internal medicine. Dr. Levy’s academic career includes 23 years at Weill-Cornell Medical College and New York Presbyterian Hospital. Levy earned his B.A. in chemistry and physics, cum laude, from Harvard College and his doctor of medicine degree from Harvard Medical School.


KARL G. TRASS
Vice President, Regulatory Affairs & Quality Assurance

Karl G. Trass joined NTI in January 2005 and has over twelve years of regulatory affairs experience, including supervising the preparation and filing of both new drug applications and biologics applications, which resulted in four compounds receiving FDA marketing approval. Mr. Trass has extensive experience in a variety of therapeutic areas, including oncology and cardiovascular, and has had significant regulatory experience outside of the U.S. Trass was Director of Regulatory Affairs with Sangamo BioSciences of Richmond, CA. He held the same position at Gilead Sciences in Foster City, CA, and was Associate Director of Regulatory Affairs for Tularik in South San Francisco. Earlier, he was Senior Manager for Regulatory Affairs at Genentech, also in South San Francisco, and Senior Associate for Regulatory Affairs with Syntex of Palo Alto. Trass holds a bachelor's degree in chemistry from Indiana University.